DOLATROX®hcc is the first medical device of Kolinpharma SPA launched in January 2021. It is a pre-filled syringe based on hyaluronic acid, chondroitin sulfate and cyclodextrin.
Dolatrox hcchcc is a medical device with CE mark in compliance with the MDD 93/42 / EEC directive and subsequent amendments and additions, containing hyaluronic acid obtained by fermentation and not chemically modified, chondroitin sulphate of marine origin and cyclodextrin. Dolatrox hcchcc is a clear, sterile, non-pyrogenic and viscoelastic solution supplied in a 3 ml syringe to be applied for pain and reduced mobility.
Thanks to the viscosifying capacity of the cyclodextrins, the solution of hyaluronic acid and chondroitin sulphate thus obtained has physical characteristics such as to guarantee better effectiveness. Dolatrox hcc acts only at the level of the joint where it is injected, without exerting any systemic action.
Hyaluronic acid sodium salt (20 mg / ml), chondrotin sulfate of marine origin (20 mg / ml), hydroxypropyl-beta-cyclodextrin (10 mg / ml), sodium chloride, sodium phosphate and water for injections (to taste).
The product is marketed also as ViJoint hcc/60.
Cyclodextrin increases solubility and stability of hyaluronic acid in water and delays the breakdown of hyaluronic acid and chondroitin sulfate in the joint. Presence of cyclodextrin in the product contributes to stability of components without the need for adding organic solvents that can cause allergic reactions.